Garfield Alastair sold $913K of RYTM
Garfield Alastair (Chief Scientific Officer) sold 7,763 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $117.57 ($116.11–$119.17, $0.91M total) across 4 trades on 2026-08-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
No new company-specific operational, financial, or regulatory information is disclosed. The only actionable item is the insider’s sale details and the confirmation it was under a 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment monitoring, but it is unlikely to change valuation without accompanying fundamental news.
What to watch
The trades were executed on 2026-08-13 under a pre-arranged 10b5-1 plan, so the sale likely reflects planning rather than new information about near-term prospects.
Background
This is an SEC Form 4 insider transaction by Garfield Alastair, Chief Scientific Officer of Rhythm Pharmaceuticals, reported on 2026-08-17.
Ticker impact
Rhythm Pharmaceuticals disclosed a Chief Scientific Officer open-market sale of 7,763 shares at about $117.57 via a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4; any impact would be sentiment-driven and short-lived.
Form 4 details an insider’s planned open-market disposition, not a company fundamental change. The disclosed size is moderate relative to typical large-cap liquidity, and the 10b5-1 framing reduces inference about new negative information.
Market effects
Minimal sector read-through; this is company-specific insider activity without clinical, regulatory, or product catalysts.
None.
None.
Counterpoint
Insider sales can be driven by diversification or tax planning, so the market may overreact to the headline framing of “sold” shares.
Key entities
- issuerRhythm Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction; ticker RYTM.
- insiderGarfield Alastair
Chief Scientific Officer who sold 7,763 shares across four trades.
- trading mechanism10b5-1 plan
Pre-arranged plan indicating the sale was scheduled in advance.
